Bispecific antibody · developed by MoonLake Immunotherapeutics
Sonelokimab (ALX-0761, M-1095) is an antibody studied in psoriatic arthritis and hidradenitis suppurativa.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06641089 | Phase 3 | Arthritis, Psoriatic | Active not recruiting | MLTX |
| NCT05322473 | Phase 2 | Hidradenitis Suppurativa | Completed | MLTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Arthritis, PsoriaticHidradenitis Suppurativa
Updated Nov 15, 2026. Something wrong or missing? Report it on the MLTX page.
See MLTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MLTX catalysts and pipeline →